e-learning
resources
Vienna 2012
Wednesday, 05.09.2012
COPD exacerbation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level
T. Pertseva, K. Gashynova, O. Bratus, N. Petrik (Dnipropetrovs, Ukraine)
Source:
Annual Congress 2012 - COPD exacerbation
Session:
COPD exacerbation
Session type:
Poster Discussion
Number:
4825
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Pertseva, K. Gashynova, O. Bratus, N. Petrik (Dnipropetrovs, Ukraine). COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level. Eur Respir J 2012; 40: Suppl. 56, 4825
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Risk factors associated with the development of interstitial lung abnormalities
Related content which might interest you:
COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012
Lymphocyte-to-Monocyte ratio (LMR) and Platelet-to-lymphocyte (PLR) ratio levels as a predictors of lung failure in severe Covid-19 pneumonia patients (pts)
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Mucociliary clearance (MCC) disorders in patient with acute bronchitis (AB) and acute exacerbation (AE) of COPD and ways of it correction
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI)
Source: Annual Congress 2013 –Lung infections: a clinical point of view
Year: 2013
Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP)
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015
Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014
Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 805s
Year: 2006
Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples
Source: Eur Respir J 2005; 26: Suppl. 49, 595s
Year: 2005
The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD)
Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles
Year: 2010
Influence of bacterial colonization (BC) on the level of systemic inflammatory markers (SIM) in COPD patients (pts)
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Effects of an acute exacerbation requiring hospitalisation (AE) on lung function, muscle force and serum IGF-I levels in male patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 564s
Year: 2002
Dose-dependent effects of salbutamol (S) and fenoterol (F) in patients with bronchial asthma (BA) and ischaemic heart disease (IHD)
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001
LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE)
Source: International Congress 2019 – Exacerbations of airway diseases
Year: 2019
Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD
Source: International Congress 2015 – Different data in COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept